Showing 1 to 2 of 2 results


Keytruda's $30 Billion Success: Revolutionizing Cancer Treatment
Keytruda, Merck's immunotherapy drug, generated nearly $30 billion in 2024 sales, marking a paradigm shift in cancer treatment since its 2014 launch, building upon research dating back to the late 19th century.
Keytruda's $30 Billion Success: Revolutionizing Cancer Treatment
Keytruda, Merck's immunotherapy drug, generated nearly $30 billion in 2024 sales, marking a paradigm shift in cancer treatment since its 2014 launch, building upon research dating back to the late 19th century.
Progress
48% Bias Score

Chinese Biotech Drug Outperforms Keytruda in Clinical Trials
Akeso's new lung cancer drug, Ivonescimab, outperformed Merck's Keytruda in Chinese clinical trials, extending progression-free survival; this success, coupled with increased licensing deals, highlights the rise of China's pharmaceutical innovation, though challenges in consumer trust and regulatory...

Chinese Biotech Drug Outperforms Keytruda in Clinical Trials
Akeso's new lung cancer drug, Ivonescimab, outperformed Merck's Keytruda in Chinese clinical trials, extending progression-free survival; this success, coupled with increased licensing deals, highlights the rise of China's pharmaceutical innovation, though challenges in consumer trust and regulatory...
Progress
48% Bias Score
Showing 1 to 2 of 2 results